Search - tctmd.com

Displaying 161 - 180 of 763

Sort: Relevancy | Date

News Conference News TCT 2019

LEVANT: Patient-Level Data Show No Increase in 5-Year Death for Paclitaxel DCBs in PAD

L.A. McKeown

September 28, 2019

News Opinion Editor's Corner TCT 2019

TCT 2019 Day Three: Thowback Saturday Revisits COAPT, PARTNER 2A, and EXCEL

Shelley Wood

September 28, 2019

News Conference News TCT 2019

‘Spooky’ Signal Still Haunts Paclitaxel DCBs in PAD, but Updated Analysis Reassures

L.A. McKeown

September 28, 2019

Presentation TCT 2019

Sustained Limus Release-Designed Drug-Eluting Balloons: Is This the Solution for the Potential Increased Mortality With Paclitaxel Devices When Treating the SFA?

Presenter: Thomas Zeller

September 27, 2019

Presentation TCT 2019

Clinical Randomized Trial Evaluating Novel, Microcrystalline, and Biocompatible Polymer Paclitaxel-Coated Balloon for the Treatment of Femoro-Popliteal Occlusive Disease: 3-Year Clinical and Ambulatory Outcome

Presenter: Piotr Buszman

September 27, 2019

Presentation TCT 2019

Clinical Outcome at 6 Months Between Paclitaxel-Coated Balloon vs. Sirolimus-Coated Balloon in De Novo Coronary Lesions

Presenter: Sandeep Basavarajaiah

September 27, 2019

Presentation TCT 2019

Absence of Risk of Death After Coronary Paclitaxel-Coated Balloons: Systematic Review and Meta-Analysis of Randomized Trials

Presenter: Bruno Scheller

September 27, 2019

Presentation TCT 2019

Treating Challenging SFA Disease in the Era of Paclitaxel Uncertainty

Presenter: Aravinda Nanjundappa

September 27, 2019

Presentation TCT 2019

Emerging Safety Signals and FDA’s Medical Device Safety Action Plan: Responses to the Late Mortality Signal

Presenter: Rebecca Ward

September 26, 2019

Presentation TCT 2019

Potential Study Designs to Address the Mortality Safety Signal

Presenter: Laura Mauri

September 26, 2019

Presentation TCT 2019

Informed Consent and Impact on Clinical Practice: A Clinician’s Perspective and a Pathway Forward

Presenter: Sahil Parikh

September 26, 2019

Presentation TCT 2019

Drug-Eluting Technologies for SFA Disease: Industry’s Perspective and a Pathway Forward

Presenter: Ian Meredith AM

September 26, 2019

Presentation TCT 2019

Is Paclitaxel-Related Mortality From SFA Drug-Eluting Technologies Biologically Plausible?

Presenter: Elazer Edelman

September 26, 2019

Presentation TCT 2019

Paclitaxel-Coated Devices for SFA Disease: An Independent, Patient-Level Meta-Analysis and Other Emerging Data

Presenter: Krishna Rocha-Singh

September 26, 2019

Presentation TCT 2019

New Insights From Our Meta-Analysis of Paclitaxel-Coated Device Randomized Trials for SFA Disease (And the Response It Has Generated)

Presenter: Konstantinos Katsanos

September 26, 2019

Presentation TCT 2019

1-Year Late Lumen Loss With a Polymer-Coated Paclitaxel-Eluting Stent and a Polymer-Free Paclitaxel-Coated Stent for Femoropopliteal Disease: Study Results

Presenter: Daizo Kawasaki

September 26, 2019

Presentation TCT 2019

Mortality Risk Following Application of Paclitaxel-Coated Devices in Femoropopliteal Lesion: Results From the CAROOT Study

Presenter: Yoshimitsu Soga

September 26, 2019

Presentation TCT 2019

Safety of PTX Devices for PAD in Japan: Academic View

Presenter: Masato Nakamura

September 26, 2019

Presentation TCT 2019

Statistical Considerations: Competing Risk, Pooling Data, RCT vs. Observational Data

Presenter: Roseann White

September 26, 2019

Presentation TCT 2019

Moving From “Signal Detection” to “Signal Discernment”: An FDA View

Presenter: Eleni Whatley

September 26, 2019

Advertisement

LEVANT: Patient-Level Data Show No Increase in 5-Year Death for Paclitaxel DCBs in PAD

TCT 2019 Day Three: Thowback Saturday Revisits COAPT, PARTNER 2A, and EXCEL

‘Spooky’ Signal Still Haunts Paclitaxel DCBs in PAD, but Updated Analysis Reassures

Sustained Limus Release-Designed Drug-Eluting Balloons: Is This the Solution for the Potential Increased Mortality With Paclitaxel Devices When Treating the SFA?

Clinical Randomized Trial Evaluating Novel, Microcrystalline, and Biocompatible Polymer Paclitaxel-Coated Balloon for the Treatment of Femoro-Popliteal Occlusive Disease: 3-Year Clinical and Ambulatory Outcome

Clinical Outcome at 6 Months Between Paclitaxel-Coated Balloon vs. Sirolimus-Coated Balloon in De Novo Coronary Lesions

Absence of Risk of Death After Coronary Paclitaxel-Coated Balloons: Systematic Review and Meta-Analysis of Randomized Trials

Treating Challenging SFA Disease in the Era of Paclitaxel Uncertainty

Emerging Safety Signals and FDA’s Medical Device Safety Action Plan: Responses to the Late Mortality Signal

Potential Study Designs to Address the Mortality Safety Signal

Informed Consent and Impact on Clinical Practice: A Clinician’s Perspective and a Pathway Forward

Drug-Eluting Technologies for SFA Disease: Industry’s Perspective and a Pathway Forward

Is Paclitaxel-Related Mortality From SFA Drug-Eluting Technologies Biologically Plausible?

Paclitaxel-Coated Devices for SFA Disease: An Independent, Patient-Level Meta-Analysis and Other Emerging Data

New Insights From Our Meta-Analysis of Paclitaxel-Coated Device Randomized Trials for SFA Disease (And the Response It Has Generated)

1-Year Late Lumen Loss With a Polymer-Coated Paclitaxel-Eluting Stent and a Polymer-Free Paclitaxel-Coated Stent for Femoropopliteal Disease: Study Results

Mortality Risk Following Application of Paclitaxel-Coated Devices in Femoropopliteal Lesion: Results From the CAROOT Study

Safety of PTX Devices for PAD in Japan: Academic View

Statistical Considerations: Competing Risk, Pooling Data, RCT vs. Observational Data

Moving From “Signal Detection” to “Signal Discernment”: An FDA View

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content